Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Up 136.0% in December

Aadi Bioscience, Inc. (NASDAQ:AADI) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 547,500 shares, an increase of 136.0% from the December 15th total of 232,000 shares. Approximately 2.7% of the shares of the company are short sold. Based on an average daily volume of 322,600 shares, the days-to-cover ratio is presently 1.7 days.

Hedge Funds Weigh In On Aadi Bioscience

Several institutional investors and hedge funds have recently bought and sold shares of the company. BML Capital Management LLC purchased a new position in shares of Aadi Bioscience during the 3rd quarter valued at $4,120,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Aadi Bioscience in the 2nd quarter valued at about $37,000. Finally, XTX Topco Ltd bought a new stake in Aadi Bioscience in the 3rd quarter valued at about $32,000. 52.08% of the stock is owned by institutional investors.

Aadi Bioscience Price Performance

NASDAQ AADI opened at $3.02 on Tuesday. The stock has a market capitalization of $74.43 million, a price-to-earnings ratio of -1.32 and a beta of 0.65. The business’s fifty day moving average is $2.61 and its 200-day moving average is $2.03. Aadi Bioscience has a one year low of $1.21 and a one year high of $3.81.

Aadi Bioscience (NASDAQ:AADI) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.46) EPS for the quarter, hitting the consensus estimate of ($0.46). Aadi Bioscience had a negative net margin of 246.06% and a negative return on equity of 71.87%. The business had revenue of $7.21 million for the quarter, compared to analyst estimates of $6.55 million. During the same quarter in the previous year, the firm posted ($0.60) earnings per share. Research analysts expect that Aadi Bioscience will post -1.78 EPS for the current fiscal year.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.